Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02041429 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01857193 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 132 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 13, 2021 | clinicaltrials |
| NCT03507543 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02952729 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | completed | Phase 1 | 120 | Mersana TherapeuticsINDUSTRY | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02139358 | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | completed | Phase 1 / Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02650752 | Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00442260 | Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 2 | West Virginia UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01289353 | Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 92 | NYU Langone HealthOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT01323530 | A Confirmation Study of Eribulin in Combination With Capecitabine | completed | Phase 1 / Phase 2 | 76 | Eisai LimitedINDUSTRY | 3 | Jan 11, 2021 | clinicaltrials |
| NCT02632071 | ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | completed | Phase 1 | 17 | Columbia UniversityOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 18 | Kathy MillerOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT02517593 | Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake(GENRE) | completed | Phase 1 / Phase 2 | 151 | Mayo ClinicOTHER | 2 | Dec 30, 2020 | clinicaltrials |
| NCT00424983 | Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT00788931 | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02375958 | PCA062 in pCAD-positive Tumors. | completed | Phase 1 | 47 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT00526045 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT00600275 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02088684 | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT00620594 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | completed | Phase 1 | 183 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01471847 | A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01626209 | A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01068483 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | completed | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT00290745 | Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ | completed | Phase 1 / Phase 2 | 79 | University of California, San FranciscoOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01192308 | PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)(KINETAM) | completed | Phase 1 | 42 | Radboud University Medical CenterOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT02757651 | KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response | completed | Phase 1 / Phase 2 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03135951 | Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy | completed | Phase 1 | 26 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00574587 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | completed | Phase 1 / Phase 2 | 55 | Albert Einstein College of MedicineOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02907021 | Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2(SCHOLAR) | completed | Phase 1 | 20 | Population Health Research InstituteOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT00033514 | Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression | completed | Phase 1 / Phase 2 | 27 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02316509 | A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 1 | 43 | Genentech, Inc.INDUSTRY | 2 | Oct 5, 2020 | clinicaltrials |
| NCT01983501 | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | completed | Phase 1 | 57 | Seagen Inc.INDUSTRY | 2 | Sep 21, 2020 | clinicaltrials |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT01973309 | A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03384316 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT01162200 | Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer | completed | Phase 1 | 75 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2021source: clinicaltrials